Thyrocare Technologies Announces Solid FY26 Performance, Recommends ₹7 Dividend, Appoints New Auditor

Thyrocare Technologies Ltd posted consolidated revenue of ₹846.03 crore for the fiscal year ended March 31, 2026.
The company reported a consolidated profit after tax (PAT) of ₹162.85 crore.

Reader Takeaway: Robust revenue growth drives profit; intense competition remains a watchpoint.

What just happened (today’s filing)

Thyrocare's Board of Directors approved the audited FY26 standalone and consolidated financial results on May 7, 2026.

Consolidated profit after tax (PAT) stood at ₹162.85 crore, on a total income of ₹846.03 crore.

The board recommended a final dividend of ₹7.00 per equity share for shareholder approval.

Price Waterhouse Chartered Accountants LLP has been appointed as the new statutory auditors for a five-year term.

An investment of up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics Private Limited, was also approved.

Why this matters

The FY26 results reflect Thyrocare's continued operational strength and financial stability.

The recommended dividend payout is a direct return to shareholders, acknowledging their investment.

Appointing a new, reputable auditor ensures robust financial oversight and compliance.

The investment in the subsidiary signals a strategic intent to fuel future business expansion.

The backstory (grounded)

Thyrocare completed a significant 1:5 bonus issue in October 2023.

This corporate action adjusted per-share metrics like EPS and dividend payouts for comparative financial analysis.

Think Health Diagnostics Private Limited operates as a key subsidiary, integral to Thyrocare's broader service delivery and strategic objectives.

What changes now

Shareholders will soon vote on the proposed final dividend of ₹7.00 per share.

Price Waterhouse Chartered Accountants LLP will assume statutory audit responsibilities for the next five fiscal years.

The subsidiary, Think Health Diagnostics, is poised for growth with the approved capital infusion.

Board composition has been updated with the appointment of additional directors and the acceptance of resignations.

Peer comparison

Thyrocare's FY26 consolidated revenue of ₹846 crore and PAT of ₹162.85 crore place it competitively.

Dr. Lal PathLabs reported FY26 revenue of ₹1,065.7 crore and PAT of ₹154.5 crore.

Metropolis Healthcare posted FY26 revenue of ₹1,024.9 crore and PAT of ₹142.1 crore.

Vijaya Diagnostic Centre's FY26 revenue was ₹831.3 crore with PAT of ₹140.8 crore.

Context metrics (time-bound)

Consolidated Revenue: ₹641.20 crore (FY24) to ₹846.03 crore (FY26).

Consolidated Profit After Tax: ₹116.21 crore (FY24) to ₹162.85 crore (FY26).

Consolidated Total Dividend per Share: ₹6.50 (FY24) to ₹9.33 (FY26).

What to track next

Shareholder approval for the recommended final dividend of ₹7.00 per share.

Ratification of the appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors.

Performance updates from the subsidiary, Think Health Diagnostics, post investment.

Future financial reports reflecting operational growth and strategic initiatives.

The effectiveness of the new auditor in ensuring financial integrity and compliance.